Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

The short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represe...

Source: BMC Nephrology - April 23, 2019 Category: Urology & Nephrology Authors: Hayley Bennett, Phil McEwan, Karina Hamilton and Karl O ’Reilly Tags: Research article Source Type: research